120 results on '"Swindle A"'
Search Results
2. Methods Used for the Applicability of Real-World Data Sources to Individual Patient Decision Making
3. Ensuring Applicability Of Real World Evidence To Individual Patient Decision Making
4. Colesevelam hcl or ezetimibe for hypercholesterolemia: differences in patient characteristics from a health care database
5. PDB68 Physician Beliefs About Insulin Pens Versus Vials, Therapy Choice Factors, and Patient Characteristics Among Elderly Type 2 Diabetes Patients
6. PND13 Economic Burden of Lennox-Gastaut Syndrome
7. Methodological challenges in calculation of daily average consumption (DACON) for GLP-1 receptor agonist injectables from claims data
8. PSY14 REAL-WORLD USE OF DULOXETINE FOR CHRONIC LOW BACK PAIN: TREATMENT PATTERN AND COSTS
9. Ensuring Applicability Of Real World Evidence To Individual Patient Decision Making
10. PMH75 PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE
11. PMH6 IMPACT OF COMORBIDITIES ON ANTIDEPRESSANT INITIATION: DULOXETINE, VENLAFAXINE, AND ESCITALOPRAM VERSUS OTHER SSRIS
12. PDB38 PREVALENCE OF OTHER DIABETES-ASSOCIATED COMPLICATIONS AND ITS IMPACT ON HEALTH CARE CHARGES AMONG PATIENTS WITH DIABETIC NEUROPATHY
13. PMH68 CHANGES OVER TIME IN PATIENT CHARACTERISTICS FOLLOWINGTHE INTRODUCTION OF DULOXETINE: A 24 MONTHS STUDY
14. PMH34 PHARMACOLOGIC TREATMENT OF GENERALIZED ANXIETY DISORDER WITH COMORBID DEPRESSION AND PAIN CONDITIONS
15. PMH17 TREATMENT COSTS OF COMORBID GENERALIZED ANXIETY DISORDER, DEPRESSION AND PAIN
16. PIHI8 DIRECT COSTS OF ERECTILE DYSFUNCTION IN A MANAGED CARE SETTING-EVIDENCE FROM A LARGE NATIONAL CLAIMS DATABASE
17. PMH32 APPROPRIATENESS AND VARIATION IN DRUG UTILIZATION ACROSS PATIENTS WITH DEPRESSION
18. Assessing the impact of a medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression
19. Daily Dose and Costs Associated With Maintenance Therapy of Topical Testosterone Agents Among Hypogonadal Men
20. Units and costs per day per claim of comparable insulins supplied to medicaid patients
21. Methodological challenges in calculation of daily average consumption (DACON) for GLP-1 receptor agonist injectables from claims data
22. PNP11: MEDICAL CARE COSTS FOR TREATING ATTENTION DEFICIT/HYPERACTIVITY DISORDER—AN EMPIRICAL STUDY BASED ON A LARGE ADMINISTRATIVE CLAIM DATA
23. Daily Dose and Costs Associated With Maintenance Therapy of Topical Testosterone Agents Among Hypogonadal Men
24. PMH34 DETERMINANTS IN ANTIDEPRESSANT TREATMENT SELECTION FOLLOWING THE INTRODUCTION OF DULOXETINE
25. Colesevelam hcl or ezetimibe for hypercholesterolemia: differences in patient characteristics from a health care database
26. Assessing the impact of a medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression
27. PDB68 Physician Beliefs About Insulin Pens Versus Vials, Therapy Choice Factors, and Patient Characteristics Among Elderly Type 2 Diabetes Patients
28. PDB7 Clinical and Resource Utilization Outcomes: Elderly Type 2 Diabetes Patients Initiating Insulin Pens Versus Vials
29. PND13 Economic Burden of Lennox-Gastaut Syndrome
30. OR3 THE DIRECT AND INDIRECT COSTS ASSOCIATED WITH HYPOGONADISM AMONG PRIVATELY-INSURED EMPLOYEES IN THE UNITED STATES
31. PMH32 COMPARISON OF REAL-WORLD HEALTH CARE COSTS AFTER THE INITIATION OF SECOND-LINE DULOXETINE OR GENERIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH MAJOR DEPRESSIIVE DISORDER
32. MH3 DEPRESSION IN PRIMARY CARE: TREATMENT AND RESPONSE
33. PSY14 REAL-WORLD USE OF DULOXETINE FOR CHRONIC LOW BACK PAIN: TREATMENT PATTERN AND COSTS
34. PMS19 REAL-WORLD USE OF DULOXETINE FOR LOW BACK PAIN AND CHRONIC LOW BACK PAIN: TREATMENT PATTERN, DIRECT AND INDIRECT COSTS
35. PMH6 IMPACT OF COMORBIDITIES ON ANTIDEPRESSANT INITIATION: DULOXETINE, VENLAFAXINE, AND ESCITALOPRAM VERSUS OTHER SSRIS
36. PMH75 PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE
37. PSY31 REAL-WORLD USE OF DULOXETINE FOR LOW BACK PAIN
38. PMH67 CLINICAL CHARACTERISTICS AMONG ANTIDEPRESSANT INITIATORS
39. PDB38 PREVALENCE OF OTHER DIABETES-ASSOCIATED COMPLICATIONS AND ITS IMPACT ON HEALTH CARE CHARGES AMONG PATIENTS WITH DIABETIC NEUROPATHY
40. PDB35 CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS WITH DIABETIC NEUROPATHY
41. PMH84 PREDICTORS OFTREATMENT INITIATION OF DULOXETINE VS. VENLAFAXINE XR FOR PATIENTS WITH MAJOR DEPRESSION DISORDER IN MANAGED CARE SETTINGS
42. PDB39 FACTORS ASSOCIATED WITH HIGH TREATMENT CHARGES IN PATIENTS WITH DIABETIC NEUROPATHY
43. PMH68 CHANGES OVER TIME IN PATIENT CHARACTERISTICS FOLLOWINGTHE INTRODUCTION OF DULOXETINE: A 24 MONTHS STUDY
44. PDB41 MEDICAL CARE OF PATIENTS WITH DIABETIC NEUROPATHY: IMPACT OF TYPE I DIABETES AND PRESENCE OF OTHER DIABETES-RELATED COMPLICATIONS
45. PMH16 PREDICTORS OF HIGH COSTS FOR GENERALIZED ANXIETY DISORDER WITH OR WITHOUT PAIN
46. PMH34 PHARMACOLOGIC TREATMENT OF GENERALIZED ANXIETY DISORDER WITH COMORBID DEPRESSION AND PAIN CONDITIONS
47. PMH17 TREATMENT COSTS OF COMORBID GENERALIZED ANXIETY DISORDER, DEPRESSION AND PAIN
48. PAA2 EXACERBATION RATES FOR SINGLE VS. DUAL CONTROLLER THERAPY FOR MILD-PERSISTENT ASTHMA
49. PMH1 CHANGES IN COMORBIDITIES, MEDICATION USE AND TREATMENT COSTS AFTER DIAGNOSIS OF GENERALIZED ANXIETY DISORDER
50. PMH67 CLINICAL CHARACTERISTICS AMONG ANTIDEPRESSANT INITIATORS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.